Skip to main content

Market Overview

Celsion Receives Fast Track Tag In US For Ovarian Cancer Immunotherapy

  • The FDA has designated Fast Track status to Celsion Corporation's (NASDAQ: CLSN) GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy for advanced ovarian cancer.
  • Fast Track status provides more frequent interaction with the FDA review team and a rolling review of the marketing application.
  • GEN-1 is currently in Phase 2 OVATION study, which combines GEN-1 with standard-of-care neoadjuvant chemotherapy in patients newly diagnosed with Stage 3/4 ovarian cancer.
  • The study's primary endpoint is two show the equivalent of a 33% improvement in progression-free survival compared with the control arm (standard of care alone).
  • Price Action: CLSN shares rally 74.7% at $3.32 in premarket trading on the last check Monday.

Related Articles (CLSN)

View Comments and Join the Discussion!

Posted-In: FDA Fast Track Ovarian CancerBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at